TNF-alpha and annexin A2: inflammation in thrombotic primary antiphospholipid syndrome

[1]  朱剑,et al.  Antiphospholipid Syndrome , 2017, Springer International Publishing.

[2]  S. Yasuda,et al.  Complement and thrombosis in the antiphospholipid syndrome. , 2016, Autoimmunity reviews.

[3]  J. Chapman,et al.  Annexin A2, autoimmunity, anxiety and depression. , 2016, Journal of autoimmunity.

[4]  M. Bećarević,et al.  Proinflammatory proteins in female and male patients with primary antiphospholipid syndrome: preliminary data , 2016, Clinical Rheumatology.

[5]  M. Bećarević.  The IgG and IgM isotypes of anti-annexin A5 antibodies: relevance for primary antiphospholipid syndrome , 2016, Journal of Thrombosis and Thrombolysis.

[6]  N. Kim,et al.  Polymorphisms in tumor necrosis factor-alpha (-863C>A, -857C>T and +488G>A) are associated with idiopathic recurrent pregnancy loss in Korean women. , 2016, Human immunology.

[7]  M. Bećarević,et al.  The IgM isotype of anti-annexin A5 antibodies and multiple positivity of conventional antiphospholipid antibodies: increasing the number of clinical manifestations of primary antiphospholipid syndrome , 2016, Clinical Rheumatology.

[8]  N. Mackman,et al.  Antiphospholipid antibody-mediated effects in an arterial model of thrombosis are dependent on Toll-like receptor 4 , 2016, Lupus.

[9]  S. Sciascia,et al.  Antiphospholipid syndrome. , 2016, Best practice & research. Clinical rheumatology.

[10]  L. L. van den Hoogen,et al.  Delineating the deranged immune system in the antiphospholipid syndrome. , 2016, Autoimmunity reviews.

[11]  R. Kretsinger,et al.  The native structure of annexin A2 peptides in hydrophilic environment determines their anti-angiogenic effects. , 2015, Biochemical pharmacology.

[12]  T. Koike,et al.  Obstetric antiphospholipid syndrome: a recent classification for an old defined disorder. , 2014, Autoimmunity reviews.

[13]  M. Petri,et al.  14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends. , 2014, Autoimmunity reviews.

[14]  L. Sedger,et al.  TNF and TNF-receptors: From mediators of cell death and inflammation to therapeutic giants - past, present and future. , 2014, Cytokine & growth factor reviews.

[15]  E. Kruithof,et al.  Receptors involved in cell activation by antiphospholipid antibodies. , 2013, Thrombosis research.

[16]  Hong Zhou,et al.  Anti-β(2)GPI/β(2)GPI induced TF and TNF-α expression in monocytes involving both TLR4/MyD88 and TLR4/TRIF signaling pathways. , 2013, Molecular immunology.

[17]  S. Prakash,et al.  Association of CTLA-4 and TNF-α polymorphism with recurrent miscarriage among North Indian women. , 2012, Cytokine.

[18]  F. Betsou,et al.  Antibodies against the N-terminal domain of annexin A2 in antiphospholipid syndrome. , 2012, European journal of internal medicine.

[19]  T. Rème,et al.  Clinical and prognostic role of annexin A2 in multiple myeloma. , 2012, Blood.

[20]  L. Trespidi,et al.  Obstetric and vascular APS: Same autoantibodies but different diseases? , 2012, Lupus.

[21]  Shuhan Sun,et al.  Alterations of profibrinolytic receptor annexin A2 in pre-eclampsia: a possible role in placental thrombin formation. , 2012, Thrombosis research.

[22]  M. Aringer,et al.  Therapeutic blockade of TNF in patients with SLE-promising or crazy? , 2012, Autoimmunity reviews.

[23]  C. Galarza-Maldonado,et al.  Obstetric antiphospholipid syndrome. , 2012, Autoimmunity reviews.

[24]  M. Bećarević,et al.  Deterioration of thromboses in primary antiphospholipid syndrome: TNF-alpha and anti-annexin A5 antibodies. , 2012, Clinical laboratory.

[25]  J. Seferovic,et al.  Significant association of antiphospholipid antibodies and TNF-alpha: marker of severe atherogenic profile of patients with type II diabetes mellitus without micro and/or macrovascular complications. , 2011, Cytokine.

[26]  L. Punzi,et al.  Anti-annexins autoantibodies: their role as biomarkers of autoimmune diseases. , 2011, Autoimmunity reviews.

[27]  K. Hajjar,et al.  The annexin A2 system and vascular homeostasis. , 2011, Vascular pharmacology.

[28]  J. Sánchez-Guerrero,et al.  Autoantibodies Against the Fibrinolytic Receptor, Annexin A2, in Cerebral Venous Thrombosis , 2011, Stroke.

[29]  Cheng-de Yang,et al.  Anti-annexin II antibody is associated with thrombosis and/or pregnancy morbidity in antiphospholipid syndrome and systemic lupus erythematosus with thrombosis , 2011, Rheumatology International.

[30]  K. Furie,et al.  Annexin A2: a tissue plasminogen activator amplifier for thrombolytic stroke therapy. , 2010, Stroke.

[31]  J. Chapman,et al.  Human antiphospholipid antibodies induce TNFalpha in monocytes via Toll-like receptor 8. , 2010, Immunobiology.

[32]  J. Musial,et al.  Increased level of tumor necrosis factor-α in patients with antiphospholipid syndrome: marker not only of inflammation but also of the prothrombotic state , 2011, Rheumatology International.

[33]  K. Hajjar,et al.  Annexin A2 is involved in antiphospholipid antibody-mediated pathogenic effects in vitro and in vivo. , 2009, Blood.

[34]  P. Meroni,et al.  Pro-inflammatory genotype as a risk factor for aPL-associated thrombosis: Report of a family with multiple anti-phospholipid positive members. , 2009, Journal of autoimmunity.

[35]  T. Koike,et al.  Complement activation in patients with primary antiphospholipid syndrome , 2008, Annals of the rheumatic diseases.

[36]  K. McCrae,et al.  Annexin A2: biology and relevance to the antiphospholipid syndrome , 2008, Lupus.

[37]  D. Tanné,et al.  Interaction of inflammation, thrombosis, aspirin and enoxaparin in CNS experimental antiphospholipid syndrome , 2008, Neurobiology of Disease.

[38]  G. Choukroun,et al.  Anti-annexin II Antibodies in Systemic Autoimmune Diseases and Antiphospholipid Syndrome , 2008, Journal of Clinical Immunology.

[39]  Chan Jun-mi,et al.  International Consensus Statement on an Update of the Classification Criteria for Definite Antiphospholipid Syndrome(APS) , 2008 .

[40]  G. Valesini,et al.  Anti-β2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor α and tissue factor by signal transduction pathways involving lipid rafts , 2007 .

[41]  Hong Zhou,et al.  Involvement of annexin A2 in anti-β2GPI/β2GPI-induced tissue factor expression on monocytes , 2007, Cell Research.

[42]  J. Vishwanatha,et al.  Regulation of nucleo-cytoplasmic shuttling of human annexin A2—a proposed mechanism , 2007, Molecular and Cellular Biochemistry.

[43]  Xiaowei Liu,et al.  Toll-like receptor and antiphospholipid mediated thrombosis: in vivo studies , 2007, Annals of the rheumatic diseases.

[44]  M. Brini,et al.  Calcium signalling and disease : molecular pathology of calcium , 2007 .

[45]  G. Valesini,et al.  Anti-beta2-glycoprotein I antibodies induce monocyte release of tumor necrosis factor alpha and tissue factor by signal transduction pathways involving lipid rafts. , 2007, Arthritis and rheumatism.

[46]  F. Velasco,et al.  Antiphospholipid syndrome and tissue factor: a thrombotic couple , 2006, Lupus.

[47]  Bihui Huang,et al.  Autoantibodies against the fibrinolytic receptor, annexin 2, in antiphospholipid syndrome. , 2005, Blood.

[48]  D. Sblattero,et al.  Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. , 2005, Blood.

[49]  N. Ronda,et al.  Humoral autoimmunity against endothelium: theory or reality? , 2005, Trends in immunology.

[50]  D. Ferrara,et al.  Involvement of p38 MAPK in the up-regulation of tissue factor on endothelial cells by antiphospholipid antibodies. , 2005, Arthritis and rheumatism.

[51]  K. McCrae,et al.  Annexin A2 mediates endothelial cell activation by antiphospholipid/anti-beta2 glycoprotein I antibodies. , 2005, Blood.

[52]  L. Birnbaumer,et al.  Macrophages Induce the Inflammatory Response in the Pulmonary Arthus Reaction through Gαi2 Activation That Controls C5aR and Fc Receptor Cooperation1 , 2005, The Journal of Immunology.

[53]  A. Wolberg,et al.  Annexin A2: better left alone. , 2005, Blood.

[54]  M. Martinuzzo,et al.  Circulating levels of tissue factor and proinflammatory cytokines in patients with primary antiphospholipid syndrome or leprosy related antiphospholipid antibodies , 2005, Lupus.

[55]  J. Salmon,et al.  TNF-α Is a Critical Effector and a Target for Therapy in Antiphospholipid Antibody-Induced Pregnancy Loss1 , 2005, The Journal of Immunology.

[56]  D. Waisman,et al.  S100A10, annexin A2, and annexin a2 heterotetramer as candidate plasminogen receptors. , 2005, Frontiers in bioscience : a journal and virtual library.

[57]  D. Waisman,et al.  Specific localization of the annexin II heterotetramer in brain lipid raft fractions and its changes in spatial learning , 2004, Journal of neurochemistry.

[58]  E. Kruithof,et al.  NFκB is an Essential Intermediate in the Activation of Endothelial Cells by Anti-β2-Glycoprotein 1 Antibodies , 2002, Thrombosis and Haemostasis.

[59]  S. Moss,et al.  Annexins: from structure to function. , 2002, Physiological reviews.

[60]  E. Kruithof,et al.  NFkappaB is an essential intermediate in the activation of endothelial cells by anti-beta(2)-glycoprotein 1 antibodies. , 2002, Thrombosis and haemostasis.

[61]  R. Vaughan,et al.  Plasma Tumor Necrosis Factor α Levels and the –238* A Promoter Polymorphism in Patients with Antiphospholipid Syndrome , 2001, Thrombosis and Haemostasis.

[62]  D. Waisman,et al.  The p11 subunit of the annexin II tetramer plays a key role in the stimulation of t-PA-dependent plasminogen activation. , 1998, Biochemistry.

[63]  K. Hajjar,et al.  An endothelial cell receptor for plasminogen/tissue plasminogen activator (t-PA). II. Annexin II-mediated enhancement of t-PA-dependent plasminogen activation. , 1994, The Journal of biological chemistry.

[64]  A. Denman.  Cellular and Molecular Immunology , 1992 .